Should You Buy Neurocrine Biosciences Stock For Its Cash?

NBIXYTD+18.0%SPYYTD+11.5%XLVYTD+23.5%
Analyze NBIX →

For questions about this article or underlying research, email help@trefis.com.

Neurocrine Biosciences (NBIX) produced free cash flow equal to 6.1% of its market value over the twelve months to September 30, 2026, against 4.2% for the median S&P 500 company. A yield that far above the median is either a bargain or a sign of trouble ahead. So which is Neurocrine: a growing business on sale, or one the market expects to shrink?

Image from Pixabay

Neurocrine’s Cash Has Grown With Revenue

Neurocrine sits on the growing side, as its free cash flow has risen alongside revenue. That matters to an owner: a shareholder owns a slice of every dollar of free cash the company keeps, whether paid out or not.

Free cash flow reached $1.04 billion in the twelve months to September 2026, up from $0.593 billion a year earlier and $0.44 billion in the twelve months to September 2024. Over the latest twelve months, revenue hit $3.7 billion, up 38.0% from a year earlier.

This cash comes from drugs that cost little to make, and Neurocrine kept 97.7% of its revenue as gross profit over the last twelve months. The business also needs little capital spending, which took 2.7% of the cash its operations brought in. At September 30, 2026, Neurocrine held $0.738 billion of cash and short-term investments against $0.392 billion of debt, providing more than enough to repay all of it.

Most Of Neurocrine’s Sales Come From One Drug

In fiscal 2025, INGREZZA, Neurocrine’s drug in the tardive dyskinesia market, brought in $2.51 billion of the company’s $2.86 billion in revenue. A company that leans that heavily on one drug is exposed to that drug’s price, and so is its stock.

Management itself has named that exposure. On the fiscal Q3 2026 call on November 2, 2026, management said it expects double-digit INGREZZA volume growth in 2027 to more than offset mid- to high single-digit net pricing headwinds. That remains a forecast, not a result. INGREZZA’s sales reached $801 million in fiscal Q3 2026, up 17% from a year earlier, and management said those sales included a $20 million benefit from customer order timing that it expects to reverse in the fourth quarter.

Management’s own forecast for the drug in fiscal 2026 has moved higher. In the November 2, 2026 release, the company lifted its fiscal 2026 INGREZZA sales guide to a midpoint of $2.91 billion, up from $2.85 billion. Two newer drugs are adding to sales as well: CRENESSITY brought in $0.301 billion in fiscal 2025, and VYKAT XR sold $107 million in fiscal Q3 2026.

What Will Show Whether Neurocrine’s Cash Keeps Growing?

Neurocrine’s twelve-month free cash flow and INGREZZA’s net price in 2027 will show it. The twelve-month figure counts for more than any one quarter, as the quarters have been uneven. Neurocrine produced $0.384 billion of free cash flow in fiscal Q3 2026, against $0.129 billion in the quarter before.

Debt is the smaller question. At the November 13, 2026 close, Neurocrine’s debt sat at 2.3% of its market value, against 19.6% for the S&P 500. The index figure counts all its members together as one company.

For a buyer of this cash, two things stay open: whether free cash flow keeps growing once INGREZZA gives up price in 2027, and whether Neurocrine keeps holding more cash than debt. Neurocrine is expected to report its fourth quarter in February 2027. Its twelve-month free cash flow and what management says about INGREZZA’s 2027 price are the figures to read in that report.

Looking For Dividends You Can Count On?

The Trefis Income Solution owns 50 stocks with at least 10 straight years of dividends, yielding about 3x the S&P 500. In backtests it made 2.9% in 2022, when the S&P 500 fell 18.2%.

See If It Fits Your Plan

Spot an error or want more like this? Tell us in 10 seconds.